Rescula (unoprostone isopropyl) / Santen, Mallinckrodt - LARVOL DELTA

Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis. (PubMed, Clin Exp Ophthalmol) - "This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG."

Journal • Retrospective data • Review • Glaucoma • Ophthalmology

Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system. (PubMed, Australas J Dermatol) - "Our findings support an association between OPP and antiglaucoma medications; under the most stringent control for topical irritant/preservative effect by of comparison to topical eye drops, unoprostone, carteolol, betaxolol and timolol all had a significant ROR for OPP."

Adverse events • Journal • Glaucoma • Immunology • Ophthalmology

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. (PubMed, Br J Ophthalmol) - "LBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%."

Journal • Retrospective data • Review • Glaucoma • Hypertension • Ophthalmology

The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues-A systemic review and meta-analysis. (PubMed, PLoS One) - "Results of our meta-analysis suggested that topical NSAIDs may enhance the IOP lowering effect of topical PGs in glaucoma patients."

Journal • Retrospective data • Review • Glaucoma • Ocular Inflammation • Ophthalmology

Discovery, characterization, and clinical utility of prostaglandin agonists for the treatment of glaucoma. (PubMed, Br J Pharmacol) - "Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester and bimatoprost (an amide). This afforded the first marketed FP-class PG agonist analog (FP-PGA) ocular hypotensive agent, latanoprost. Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester, and bimatoprost (an amide)."

Clinical • Journal • Review • Glaucoma • Ophthalmology

Sucampo's walls are beginning to close in (SeekingAlpha) - "Rescula had generated revenues of $2.1m in Q2 2017 in comparison to $1.4m in the prior year...Rescula also happens to be approaching its patent conclusion in 2021."

Commercial • Patent • Inherited Retinal Dystrophy • Ophthalmology

Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells. (PubMed, Exp Eye Res) - "Zymography results show that all three PGAs except unoprostone increased intermediate MMP-1 activity while bimatoprost and latanoprost increased MMP-9 activity. Together, these data suggest that the balance between MMPs and TIMPs correlate to the relative intraocular pressure lowering effectiveness observed in clinical studies of these PGAs."

Journal • MMP1 • MMP3 • MMP9

LATANOPROSTENE BUNOD FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION- SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS. (ISPOR 2019) - "A search through Medline, EmBase and Pubmed to include studies published over 2014 until May 2018 was conducted.Studies were selected if they reported relative efficacy between at least two treatments (apraclonidine, brimonidine, betaxolol, carteolol, levobunolol, timolol, brinzolamide, dorzolamide, bimatoprost 0.01%, bimatroprost 0.03%, latanoprost, travoprost, tafluprost, unoprostone, latanoprostene bunod, or placebo), in IOP reduction after 3 months of usage. LBN numerically outperformed the three most widely used PGAs, namely latanoprost, travoprost and bimatoprost 0.01% in IOP reduction."

Retrospective data